Download PDF
Dtsch Med Wochenschr 2015; 140(20): 1486-1489
DOI: 10.1055/s-0041-106246
Klinischer Fortschritt
Angiologie
© Georg Thieme Verlag KG Stuttgart · New York

Thromboangiitis obliterans (Morbus Winiwater-Buerger)

Update 2015Thromboangiitis obliterans (Buergerʼs disease): update 2015
Peter Klein-Weigel
1   Klinik für Angiologie, HELIOS Klinikum Berlin-Buch, Berlin
,
Theresa Sophie Volz
1   Klinik für Angiologie, HELIOS Klinikum Berlin-Buch, Berlin
,
Jutta Richter
2   Poliklinik, Funktionsbereich & Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
07 October 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Thromboangiitis obliterans ist eine Vaskulitis mit undulierendem klinischen Verlauf und multisegmentalem Befall der kleinen und mittleren Arterien und Venen, die zu zellreichen thrombotischen Verschlüssen führt. Die Erkrankung ist an einen Tabakkonsum gebunden. Zunehmende Erkenntnisse über die Bedeutung immunologischer Mechanismen in der komplexen Pathophysiologie der Erkrankung kumulierten in der Formulierung einer neuen Autoimmunhypothese als neues Paradigma. Neue Behandlungskonzepte umfassen die Progenitorzellltherapie, die Immunadsorption, die Endothelin-Rezeptorblockade mit Bosentan und den Einsatz von Phosphodiesterase V-Inhibitoren.

Abstract

Thromboangiitis obliterans (Buergerʼs disease) is a vasculitis with undulating clinical course multisegmentarily affecting small and medium-sized arteries and veins. The disease is closely linked to tobacco-use. Increasing knowledge of autoimmunologic mechanisms in the complex pathophyiology of the disease let to the formulation of an autoimmunity-hypothesis now serving as a new paradigma. New treatment options comprise progenitor-cell-therapy, immunoadsorption, use of sendothelin-receptor-blocking agent Bosentan, and prescriptions of antiphosphodiesterase-V-inhibitors.

Schlüsselwörter

Thromboangiitis obliterans - Morbus Winiwater-Buerger - Autoimmunität - Progenitorzelltherapie - Immunadsorption - Bosentan - Phosphodiesterase-V-Hemmer - Sildenafil

Keywords

Thromboangiitis obliterans - Buergerʼs disease - autoimmunity - progenitor cell therapy - immunadsorption - bosentan - phosphodieasterase-V-inhibitors - sildenafil
 

  • Literatur

  • 1 Buerger L. Landmark publication from the American Journal of the Medical Sciences, ‚Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene‘. 1908. Am J Med Sci 2009; 337: 274-284
    CrossrefPubMedGoogle Scholar
  • 2 Dargon PT, Landry GJ. Buergerʼs disease. Ann Vasc Surg 2012; 26: 871-80
    CrossrefPubMedGoogle Scholar
  • 3 Arkkila PE. Thrombangiitis obliterans (Buergerʼs disease). Orphanet J Rare Dis 2006; 1: 14
    CrossrefPubMedGoogle Scholar
  • 4 Olin JW, Young JR, Graor RA et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger‘s disease). Circulation 1990; 825 (Suppl): IV3-8
    PubMedGoogle Scholar
  • 5 Fazeli B. Buergerʼs disease as an indicator of socioeconomic development in different societies, a cross-sectional descriptive study in the North-East of Iran. Arch Med Sci 2010; 6: 343-347
    PubMedGoogle Scholar
  • 6 Sasaki S, Sakuma M, Kunihara T, Yasuda K. Current trends in thromboangiitis obliterans (Buergerʼs disease) in women. Am J Surg 1999; 177: 316-320
    CrossrefPubMedGoogle Scholar
  • 7 Kobayashi M, Ito M, Nakagawa A et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buergerʼs disease (endarteritis obliterans). J Vasc Surg 1999; 29: 451-458
    CrossrefPubMedGoogle Scholar
  • 8 Lee T, Seo JW, Sumpio BE et al. Immunobiologic analysis of arterial tissue in Buergerʼs disease. Eur J Vasc Endovasc Surg 2003; 25: 451-457
    CrossrefPubMedGoogle Scholar
  • 9 Kim EJ, Cho BS, Lee TS et al. Morphologic change of the internal elastic lamina in buergerʼs disease. J Korean Med Sci 2000; 15: 44-48
    CrossrefPubMedGoogle Scholar
  • 10 Dellalibera-Joviliano R, Joviliano EE, Silva JS, Evora PR. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin Exp Immunol 2012; 170: 28-35
    CrossrefPubMedGoogle Scholar
  • 11 Slavov ES, Stanilova SA, Petkov DP, Dobreva ZG. Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol 2005; 23: 219-226
    PubMedGoogle Scholar
  • 12 Klein-Weigel PF, Richter JG. Thromboangiitis obliterans (Buergerʼs disease). VASA 2014; 43: 337-346
    CrossrefPubMedGoogle Scholar
  • 13 Klein-Weigel PF, Bimmler M, Hempel P et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buergerʼs disease) and their removal by immunoadsorption. Vasa 2014; 43: 347-52
    CrossrefPubMedGoogle Scholar
  • 14 Ketha SS, Cooper LT. The role of autoimmunity in thromboangiitis obliterans (Buergerʼs disease). Ann N Y Acad Sci 2013; 1285: 15-25
    CrossrefPubMedGoogle Scholar
  • 15 Shinoya S. Diagnostic criteria of Buergerʼs disease. Int J Cardiol 1988; 66 (Suppl. 01) S243-245
    PubMedGoogle Scholar
  • 16 Fazeli B, Modaghegh H, Ravrai H et al. Thrombophlebitis migrans as a footprint of Buergerʼs disease. Clin Rheumatol 2008; 27: 55-57
    CrossrefPubMedGoogle Scholar
  • 17 Hackl G, Milosavljevic R, Belaj K et al. The value of FDG-PET in the diagnosis of thromboangiitis obliterans. Clin Rheumatol 2015; 34: 739-44105
    CrossrefPubMedGoogle Scholar
  • 18 Börner C, Heidrich H. Long-term follow-up of thrombangiitis obliterans. Vasa 1998; 27: 80-86
    PubMedGoogle Scholar
  • 19 Cooper LT, Henderson SS, Ballman KV et al. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buergerʼs Disease). Angiology 2006; 57: 73-78
    CrossrefPubMedGoogle Scholar
  • 20 Fiessinger JN, Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990; 335: 555-557
    CrossrefPubMedGoogle Scholar
  • 21 Bozkurt AK, Köksal C, Demirbas MY et al. Turkish Buerger‘s Disease Research Group. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buergerʼs disease. Int Angiol 2006; 25: 162-168
    PubMedGoogle Scholar
  • 22 Bozkurt AK, Cengiz K, Arslan C et al. A stable prostacyclin analogue (iloprost) in the treatment of Buergerʼs disease. Ann Thorac Cardiovasc Surg 2013; 19: 120-125
    CrossrefPubMedGoogle Scholar
  • 23 Donas KP, Schulte S, Ktenidis K, Horsch S. The role of epidural spinal cord stimulation in the treatment of Buergerʼs disease. J Vasc Surg 2005; 41: 830-836
    CrossrefPubMedGoogle Scholar
  • 24 Vaquer Quiles L, Blasco González L, Asensio Samper J et al. Epidural neurostimulation of posterior funiculi for the treatment of Buergerʼs disease. Neuromodulation 2009; 12: 156-160
    CrossrefPubMedGoogle Scholar
  • 25 Graziani L, Morelli L, Parini F et al. Clinical outcome after extended endovascular recanalization in Buergerʼs disease in 20 consecutive cases. Ann Vasc Surg 2012; 26: 387-395
    CrossrefPubMedGoogle Scholar
  • 26 Yuan L, Bao J, Zhao Z et al. Clinical results of percutaneous transluminal angioplasty for thromboangiitis obliterans in arteries above the knee. Atherosclerosis 2014; 235: 110-115109
    CrossrefPubMedGoogle Scholar
  • 27 Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53: 445-453
    CrossrefPubMedGoogle Scholar
  • 28 Lee KB, Kang ES, Kim AK et al. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors. Int J Stem Cells 2011; 4: 88-98
    CrossrefPubMedGoogle Scholar
  • 29 Baumann G, Stangl V, Klein-Weigel P et al. Successful treatment of thromboangiitis obliterans (Buergerʼs disease) with immunoadsorption. Clin Res Cardiol 2011; 100: 683-690
    CrossrefPubMedGoogle Scholar
  • 30 Klein-Weigel P, Köning C, Härtwig A et al. Immunadsorption bei Thrombangiitis obliterans – eine vielversprechende therapeutische Option. Zentralbl Chir 2012; 137: 460-465
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Fazeli B, Rafatpanah H, Ravari H et al. Sera of patients with thromboangiitis obliterans activated cultured human umbilical vein endothelial cells (HUVECs) and changed their adhesive properties. Int J Rheum Dis 2014; 17: 106-112
    CrossrefPubMedGoogle Scholar
  • 32 Todoli Parra JA, Hernández MM, Arrébola López MA. Efficacy of bosentan in digital ischemic ulcers. Ann Vasc Surg 2010; 24: 690
    PubMedGoogle Scholar
  • 33 De Haro J, Acin F, Bleda S et al. Treatment of thromboangiitis obliterans (Buergerʼs disease) with bosentan. BMC Cardiovasc Disord 2012; 12: 15
    CrossrefPubMedGoogle Scholar
  • 34 De Haro J, Bleda S, Acin F. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buergerʼs disease). Int J Cardiol 2014; 177: 529-531
    CrossrefPubMedGoogle Scholar
  • 35 Jiménez-Gallo D, Albarrán-Planelles C, Arjona-Aguilera C et al. Treatment of thromboangiitis obliterans(Buergerʼs disease) with high-potency vasodilators. Dermatol Ther 2015; 28: 135-139
    CrossrefPubMedGoogle Scholar